Pushchino, Russian Federation
Pushchino, Russian Federation
Pushchino, Russian Federation
Avian pathogenic Escherichia coli (APEC) strains are causative agents of colibacillosis, an infectious disease that inflicts substantial commercial losses on poultry farms worldwide. The growing resistance of E. coli to antibiotics necessitates the search for alternative approaches to treat and prevent avian colibacillosis, phage therapy being one of them. This review covers 25 years of experimental studies (PubMed, Google Scholar) that examine various aspects of phage therapy with a particular focus on comparing different administration routes (with drinking water; injected orally, intratracheally, or intramuscularly; sprayed as aerosols). It also compares various techniques of introducing phage preparations to avian embryos (injections in ovo). The review describes such aspects as the general efficacy of the administration routes and their specific advantages (e. g., convenience of the aerosol-spraying technique for treating large flocks). It focuses on the advantages of multi-phage cocktails over single-phage preparations, combined antibiotic/phage therapy during colibacillosis epidemics, and administering phage preparations in nanocapsules. The review also discusses the possible interference of the avian immune system with the delivery of phage particles to the infected organs and the importance of phage selection for the success of the therapy.
Phage therapy, avian pathogenic Escherichia coli, chickens, antimicrobial resistance, coliphage, colibacillosis
1. Khairullah AR, Afnani DA, Riwu KHP, Widodo A, Yanestria SM, et al. Avian pathogenic Escherichia coli: Epidemiology, virulence and pathogenesis, diagnosis, pathophysiology, transmission, vaccination, and control. Veterinary World. 2024;17(12):2747–2762. https://doi.org/10.14202/vetworld.2024.2747-2762
2. Watts A, Wigley P. Avian pathogenic Escherichia coli: An overview of infection biology, antimicrobial resistance and vaccination. Antibiotics. 2024;13(9):809. https://doi.org/10.3390/antibiotics13090809
3. Abdelhamid MK, Hess C, Bilic I, Glösmann M, Rehman HU, et al. A comprehensive study of colisepticaemia progression in layer chickens applying novel tools elucidates pathogenesis and transmission of Escherichia coli into eggs. Scientific Reports. 2024;14:8111. https://doi.org/10.1038/s41598-024-58706-3
4. Ozaki H, Yonehara K, Murase T. Virulence of Escherichia coli isolates obtained from layer chickens with colibacillosis associated with pericarditis, perihepatitis, and salpingitis in experimentally infected chicks and embryonated eggs. Avian Diseases. 2018;62(2):233–236. https://doi.org/10.1637/11685-060717-ResNote.1
5. Paudel S, Fink D, Abdelhamid MK, Zöggeler A, Liebhart D, et al. Aerosol is the optimal route of respiratory tract infection to induce pathological lesions of colibacillosis by a lux-tagged avian pathogenic Escherichia coli in chickens. Avian Pathology. 2021;50(5):417–426. https://doi.org/10.1080/03079457.2021.1978392
6. Li LL, Xu PT, Liu ZP, Liu CA, Dong XY, et al. Effects of salpingitis simulation on the morphology and expression of inflammatory-related genes of oviduct in laying hens. Poultry Science. 2022;102(1):102246. https://doi.org/10.1016/j.psj.2022.102246
7. Nolan LK, Vaillancourt JP, Barbieri NL, Logue CM. Colibacillosis. Diseases of Poultry. Hoboken, NJ: John Wiley & Sons; 2020, pp. 770–830. https://doi.org/10.1002/9781119371199.ch18
8. Panth Y. Colibacillosis in poultry: A review. Journal of Agriculture and Natural Resources. 2019;2(1):301–311. https://doi.org/10.3126/janr.v2i1.26094
9. Konicek C, Joachim A, Spergser J, Richter B, Gumpenberger M. From livestock to companion: Admission causes, diagnostics, and clinical findings in chickens admitted to the avian clinic of the Vetmeduni Vienna, 2009–2019. Animals. 2025;15(9):1288. https://doi.org/10.3390/ani15091288
10. Nuraliev YR, Kushaliev KZ. Therapeutic and preventive measures for colibacteriosis in industrial poultry farming. Bulletin Samara State Agricultural Academy. 2021;6(2):51–57. (In Russ.)
11. Sargeant JM, Bergevin MD, Churchill K, Dawkins K, Deb B, et al. The efficacy of antibiotics to control colibacillosis in broiler poultry: A systematic review. Animal Health Research Reviews. 2019;20(2):263–273. https://doi.org/10.1017/S1466252319000264
12. Tilli G, Ngom RV, de Carvalho Ferreira HC, Apostolakos I, Paudel S, et al. A systematic review on the role of biosecurity to prevent or control colibacillosis in broiler production. Poultry Science. 2024;103(8):103955. https://doi.org/10.1016/j.psj.2024.103955
13. Ahmed S, Das T, Nath C, Ahmed T, Ghosh K, et al. Whole-genome characterization and global phylogenetic comparison of cefotaxime-resistant Escherichia coli isolated from broiler chickens. Journal of Microbiology. 2025;63(4):e2412009. https://doi.org/10.71150/jm.2412009
14. Ahmed ZS, Hashad ME, Atef Y, Badr H, Elhariri M, et al. Public health threat of antimicrobial resistance and virulence genes in Escherichia coli from human-chicken transmission in Egypt. Scientific Reports. 2025;15:12627. https://doi.org/10.1038/s41598-025-94177-w
15. Chenouf NS, Messaï CR, Carvalho I, Álvarez-Gómez T, Silva V, et al. Serogrouping and molecular characterization of ESBL-producing avian pathogenic Escherichia coli from broilers and Turkeys with colibacillosis in Algeria. Antibiotics. 2025;14(4):356. https://doi.org/10.3390/antibiotics14040356
16. Khanom H, Nath C, Mshelbwala PP, Pasha MR, Magalhaes RS, et al. Epidemiology and molecular characterisation of multidrug-resistant Escherichia coli isolated from chicken meat. PLoS One. 2025;20(5):e0323909. https://doi.org/10.1371/journal.pone.0323909
17. Laopiem S, Witoonsatian K, Kulprasetsri S, Panomwan P, Pathomchai-Umporn C, et al. Antimicrobial resistance, virulence gene profiles, and phylogenetic groups of Escherichia coli isolated from healthy broilers and broilers with colibacillosis in Thailand. BMC Veterinary Research. 2025;21:160. https://doi.org/10.1186/s12917-025-04626-x
18. Li F, Li M, Nie L, Zuo J, Fan W, et al. Molecular epidemiology and antibiotic resistance associated with avian pathogenic Escherichia coli in Shanxi province, China, from 2021 to 2023. Microorganisms. 2025;13(3):541. https://doi.org/10.3390/microorganisms13030541
19. Rahimian M, Deyhim H, Shirazi-Zavaragh S, Zeynali M, Bonabi E, et al. Phage isolation, characterization, and antibiotic resistance profiling in Avian pathogenic Escherichia coli: Integrating data for a possible novel AMR surveillance model. Microbial Pathogenesis. 2025;203:107506. https://doi.org/10.1016/j.micpath.2025.107506
20. Subhasinghe I, Bandara HMHN, Karunarathna HMTK, Kodithuwakku SP, Gallage HC, et al. Antimicrobial resistance patterns and biofilms resurgence ability of Escherichia coli associated with commercial layer chicken farms in Sri Lanka. Veterinary Microbiology. 2025;302:110422. https://doi.org/10.1016/j.vetmic.2025.110422
21. Cui L, Watanabe S, Miyanaga K, Kiga K, Sasahara T, et al. A comprehensive review on phage therapy and phage-based drug development. Antibiotics. 2024;13(9):870. https://doi.org/10.3390/antibiotics13090870
22. Fowoyo PT. Phage therapy: Clinical applications, efficacy, and implementation hurdles. The Open Microbiology Journal. 2024;18:e18742858281566. https://doi.org/10.2174/0118742858281566231221045303
23. Hatfull GF, Dedrick RM, Schooley RT. Phage therapy for antibiotic-resistant bacterial infections. Annual Review of Medicine. 2022;73:197–211. https://doi.org/10.1146/annurev-med-080219-122208
24. Kapoor A, Mudaliar SB, Bhat VG, Chakraborty I, Prasad ASB, et al. Phage therapy: A novel approach against multidrug-resistant pathogens. 3 Biotech. 2024;14:256. https://doi.org/10.1007/s13205-024-04101-8
25. Sahoo K, Meshram S. The evolution of phage therapy: A comprehensive review of current applications and future innovations. Cureus. 2024;16(9):e70414. https://doi.org/10.7759/cureus.70414
26. Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. Cell. 2023;186(1):17–31. https://doi.org/10.1016/j.cell.2022.11.017
27. Huang Y, Pang Z, Zhu X, Wang J, Gao X, et al. Characterization and genomic analysis of a broad-spectrum lytic phage vB_EcoM_SD350 and its application on raw chicken and beef meats against Avian pathogenic Escherichia coli. LWT. 2025;222:117618. https://doi.org/10.1016/j.lwt.2025.117618
28. Norambuena R, Rojas-Martínez V, Tobar-Calfucoy E, Aguilera M, Sabag A, et al. Development of a bacteriophage cocktail with high specificity against high-risk avian pathogenic Escherichia coli. Poultry Science. 2025;104(6):105038. https://doi.org/10.1016/j.psj.2025.105038
29. Quyen DV, Lanh PT, Oanh NK, Huong PVT. A lytic bacteriophage PS2 with potential for controlling salmonella infections in chickens and ducks. VNU Journal of Science: Natural Sciences and Technology. 2025;41(2). https://doi.org/10.25073/2588-1140/vnunst.5874
30. Śliwka P, Moreno DS, Korzeniowski P, Milcarz A, Kuczkowski M, et al. Avian pathogenic Escherichia coli-targeting phages for biofilm biocontrol in the poultry industry. Veterinary Microbiology. 2025;301:110363. https://doi.org/10.1016/j.vetmic.2024.110363
31. Khan F, Naseem H, Asif M, Alvi I, ur Rehman S, et al. Bacteriophages RCF and 1-6bf can control the growth of avian pathogenic Escherichia coli. Poultry Science. 2025;104(2):104790. https://doi.org/10.1016/j.psj.2025.104790
32. Li H, Xie D, Huang R, Shi B, Xie J, et al. Characterization of phage vB_EcoP_HC25 and its therapeutic effect on chicken colibacillosis. Microbial Pathogenesis. 2025;203:107490. https://doi.org/10.1016/j.micpath.2025.107490
33. Chrzastek K, Seal BS, Kulkarni A, Kapczynski DR. Whole-genome shotgun sequencing from chicken clinical tracheal samples for bacterial and novel bacteriophage identification. Veterinary Sciences. 2025;12(2):162. https://doi.org/10.3390/vetsci12020162
34. Karami M, Goudarztalejerdi A, Mohammadzadeh A, Berizi E. In vitro evaluation of two novel Escherichia bacteriophages against multiple drug resistant avian pathogenic Escherichia coli. BMC Infectious Diseases. 2024;24:497. https://doi.org/10.1186/s12879-024-09402-0
35. Jhandai P, Mittal D, Gupta R, Kumar M, Khurana R. Therapeutics and prophylactic efficacy of novel lytic Escherichia phage vB_EcoS_PJ16 against multidrug-resistant avian pathogenic E. coli using in vivo study. International Microbiology. 2024;27:673–687. https://doi.org/10.1007/s10123-023-00420-7
36. Zhang H, Su X, Zheng X, Liu M, Zhao C, et al. vB_EcoM-P896 coliphage isolated from duck sewage can lyse both intestinal pathogenic Escherichia coli and extraintestinal pathogenic E. coli. International Microbiology. 2025;28:49–60. https://doi.org/10.1007/s10123-024-00519-5
37. Wintachai P, Thaion F, Clokie MRJ, Thomrongsuwannakij T. Isolation and characterization of a novel Escherichia bacteriophage with potential to control multidrug-resistant avian pathogenic Escherichia coli and biofilms. Antibiotics. 2024;13(1):1083. https://doi.org/10.3390/antibiotics13111083
38. de Souza ALF, Stefani LCM. Isolation of lytic bacteriophages of Escherichia coli from swine. Brazilian Journal of Veterinary Research and Animal Science. 2024;61(2024):e222458. https://doi.org/10.11606/issn.1678-4456.bjvras.2024.222458
39. Nang SC, Lin YW, Petrovic Fabijan A, Chang RYK, Rao GG, et al. Pharmacokinetics/pharmacodynamics of phage therapy: A major hurdle to clinical translation. Clinical Microbiology and Infection. 2023;29(6):702–709. https://doi.org/10.1016/j.cmi.2023.01.021
40. Nobrega FL, Costa AR, Santos JF, Siliakus MF, van Lent JWM, et al. Genetically manipulated phages with improved pH resistance for oral administration in veterinary medicine. Scientific Reports. 2016;6:39235. https://doi.org/10.1038/srep39235
41. Qadir MI, Mobeen T, Masood A. Phage therapy: Progress in pharmacokinetics. Brazilian Journal of Pharmaceutical Sciences. 2018;54(1):e17093. https://doi.org/10.1590/s2175-97902018000117093
42. Zelasko S, Gorski A, Dabrowska K. Delivering phage therapy per os: Benefits and barriers. Expert Review of Anti-infective Therapy. 2017;15(2):167–179. https://doi.org/10.1080/14787210.2017.1265447
43. Zhu M, Hao C, Zou T, Jiang S, Wu B. Phage therapy as an alternative strategy for oral bacterial infections: A systematic review. BMC Oral Health. 2025;25:44. https://doi.org/10.1186/s12903-024-05399-9
44. Dąbrowska K. Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Medicinal Research Reviews. 2019;39(5):2000–2025. https://doi.org/10.1002/med.21572
45. Jończyk E, Kłak M, Międzybrodzki R, Górski A. The influence of external factors on bacteriophages – Review. Folia Microbiologica. 2011;56:191–200. https://doi.org/10.1007/s12223-011-0039-8
46. Nicolas M, Trotereau A, Culot A, Moodley A, Atterbury R, et al. Isolation and characterization of a novel phage collection against avian-pathogenic Escherichia coli. Microbiology Spectrum. 2023;11(3):e04296-22. https://doi.org/10.1128/spectrum.04296-22
47. Barrow P, Lovell M, Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clinical and Diagnostic Laboratory Immunology. 1998;5(3):294–298.
48. Baig A, Colom J, Barrow P, Schouler C, Moodley A, et al. Biology and genomics of an historic therapeutic Escherichia coli bacteriophage collection. Frontiers in Microbiology. 2017;8:1652. https://doi.org/10.3389/fmicb.2017.01652
49. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics. Journal for General Microbiology. 1982;128:307–318. https://doi.org/10.1099/00221287-128-2-307
50. Gan HM, Sieo CC, Tang SGH, Omar AR, Ho YW. The complete genome sequence of EC1-UPM, a novel N4-like bacteriophage that infects Escherichia coli O78:K80. Virology Journal. 2013;10:308. https://doi.org/10.1186/1743-422X-10-308
51. Lau GL, Sieo CC, Tan WS, Hair-Bejo M, Jalila A, et al. Efficacy of a bacteriophage isolated from chickens as a therapeutic agent for colibacillosis in broiler chickens. Poultry Science. 2010;89(12):2589–2596. https://doi.org/10.3382/ps.2010-00904
52. Tsonos J, Oosterik LH, Tuntufye HN, Klumpp J, Butaye P, et al. A cocktail of in vitro efficient phages is not a guarantee for in vivo therapeutic results against avian colibacillosis. Veterinary Microbiology. 2014;171(3–4):470–479. https://doi.org/10.1016/j.vetmic.2013.10.021
53. Kittler S, Mengden R, Korf IHE, Bierbrodt A, Wittmann J, et al. Impact of bacteriophage-supplemented drinking water on the E. coli population in the chicken gut. Pathogens. 2020;9(4):293. https://doi.org/10.3390/pathogens9040293
54. Korf IHE, Kittler S, Bierbrodt A, Mengden R, Rohde C, et al. In vitro evaluation of a phage cocktail controlling infections with Escherichia coli. Viruses. 2020;12(12):1470. https://doi.org/10.3390/v12121470
55. Kaikabo AA, Mohammed AS, Abas F. Chitosan nanoparticles as carriers for the delivery of ΦKAZ14 bacteriophage for oral biological control of colibacillosis in chickens. Molecules. 2016;21(3):256. https://doi.org/10.3390/molecules21030256
56. Ahmad KA, Mohanmmed AS, Abas F, Chin SC. T4-like coliphage ΦKAZ14 virulent to pathogenic and extended spectrum β-lactamase-producing Escherichia coli of poultry origin. Virologica Sinica. 2015;30:73–75. https://doi.org/10.1007/s12250-014-3541-8
57. Huff WE, Huff GR, Rath NC, Balog JM, Xie H, et al. Prevention of Escherichia coli respiratory infection in broiler chickens with bacteriophage (SPR02). Poultry Science. 2002;81(4):437–441. https://doi.org/10.1093/ps/81.4.437
58. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Bacteriophage treatment of a severe Escherichia coli respiratory infection in broiler chickens. Avian Diseases. 2003;47(4):1399–1405. https://doi.org/10.1637/7041
59. Naghizadeh M, Torshizi MAK, Rahimi S, Engberg RM, Dalgaard TS. Effect of serum anti-phage activity on colibacillosis control by repeated phage therapy in broilers. Veterinary Microbiology. 2019;234:61–71. https://doi.org/10.1016/j.vetmic.2019.05.018
60. Naghizadeh M, Torshizi MAK, Rahimi S, Dalgaard TS. Synergistic effect of phage therapy using a cocktail rather than a single phage in the control of severe colibacillosis in quails. Poultry Science. 2019;98(2):653–663. https://doi.org/10.3382/ps/pey414
61. Xie H, Zhuang X, Kong J, Ma G, Zhang H. Bacteriophage Esc-A is an efficient therapy for Escherichia coli 3-1 caused diarrhea in chickens. The Journal of General and Applied Microbiology. 2005;51(3):159–163. https://doi.org/10.2323/jgam.51.159
62. Li H, Ma ML, Xie HJ, Kong J. Biosafety evaluation of bacteriophages for treatment of diarrhea due to intestinal pathogen Escherichia coli 3-2 infection of chickens. World Journal of Microbiology and Biotechnology. 2012;28:1–6. https://doi.org/10.1007/s11274-011-0784-5
63. Oliveira A, Sillankorva S, Quinta R, Henriques A, Sereno R, et al. Isolation and characterization of bacteriophages for avian pathogenic E. coli strains. Journal of Applied Microbiology. 2009;106(6):1919–1927. https://doi.org/10.1111/j.1365-2672.2009.04145.x
64. Sorour HK, Gaber AF, Hosny RA. Evaluation of the efficiency of using Salmonella Kentucky and Escherichia coli O119 bacteriophages in the treatment and prevention of salmonellosis and colibacillosis in broiler chickens. Letters in Applied Microbiology. 2020;71(4):345–350. https://doi.org/10.1111/lam.13347
65. Upadhaya SD, Ahn JM, Cho JH, Kim JY, Kang DK, et al. Bacteriophage cocktail supplementation improves growth performance, gut microbiome and production traits in broiler chickens. Journal of Animal Science and Biotechnology. 2021;12:49. https://doi.org/10.1186/s40104-021-00570-6
66. Kaikabo AA, AbdulKarim SM, Abas F. Evaluation of the efficacy of chitosan nanoparticles loaded ΦKAZ14 bacteriophage in the biological control of colibacillosis in chickens. Poultry Science. 2017;96(2):295–302. https://doi.org/10.3382/ps/pew255
67. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Prevention of Escherichia coli infection in broiler chickens with a bacteriophage aerosol spray. Poultry Science. 2002;81(10):1486–1491. https://doi.org/10.1093/ps/81.10.1486
68. Oliveira A, Sereno R, Azeredo J. In vivo efficiency evaluation of a phage cocktail in controlling severe colibacillosis in confined conditions and experimental poultry houses. Veterinary Microbiology. 2010;146(3–4):303–308. https://doi.org/10.1016/j.vetmic.2010.05.015
69. Huff WE, Huff GR, Rath NC, Donoghue AM. Method of administration affects the ability of bacteriophage to prevent colibacillosis in 1-day-old broiler chickens. Poultry Science. 2013;92(4):930–934. https://doi.org/10.3382/ps.2012-02916
70. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poultry Science. 2003;82(7):1108–1112. https://doi.org/10.1093/ps/82.7.1108
71. Eid S, Tolba HMN, Hamed RI, Al-Atfeehy NM. Bacteriophage therapy as an alternative biocontrol against emerging multidrug resistant E. coli in broilers. Saudi Journal of Biological Sciences. 2022;29(5):3380–3389. https://doi.org/10.1016/j.sjbs.2022.02.015
72. Tawakol MM, Nabil NM, Samy A. Evaluation of bacteriophage efficacy in reducing the impact of single and mixed infections with Escherichia coli and infectious bronchitis in chickens. Infection Ecology & Epidemiology. 2019;9(1):1686822. https://doi.org/10.1080/20008686.2019.1686822
73. Turner D, Shkoporov AN, Lood C, Millard AD, Dutilh BE, et al. Abolishment of morphology-based taxa and change to binomial species names: 2022 taxonomy update of the ICTV bacterial viruses subcommittee. Archives of Virology. 2023;168:74. https://doi.org/10.1007/s00705-022-05694-2
74. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers. Poultry Science. 2004;83(12):1944–1947. https://doi.org/10.1093/ps/83.12.1944
75. Huff WE, Huff GR, Rath NC, Donoghue AM. Evaluation of the influence of bacteriophage titer on the treatment of colibacillosis in broiler chickens. Poultry Science. 2006;85(8):1373–1377. https://doi.org/10.1093/ps/85.8.1373
76. Huff WE, Huff GR, Rath NC, Donoghue AM. Immune interference of bacteriophage efficacy when treating colibacillosis in poultry. Poultry Science. 2010;89(5):895–900. https://doi.org/10.3382/ps.2009-00528
77. Oliveira A, Sereno R, Nicolau A, Azeredo J. The influence of the mode of administration in the dissemination of three coliphages in chickens. Poultry Science. 2009;88(4):728–733. https://doi.org/10.3382/ps.2008-00378
78. Nicolas M, Faurie A, Girault M, Lavillatte S, Menanteau P, et al. In ovo administration of a phage cocktail partially prevents colibacillosis in chicks. Poultry Science. 2023;102(11):102967. https://doi.org/10.1016/j.psj.2023.102967
79. Trotereau A, Schouler C. Use of a chicken embryo lethality assay to assess the efficacy of phage therapy. In: Clokie M, Kropinski A, Lavigne R, editors. Bacteriophages. Methods in Molecular Biology. NY: Humana Press; 2019, Vol. 1898. PP. 199–205. https://doi.org/10.1007/978-1-4939-8940-9_17
80. Kaźmierczak Z, Majewska J, Miernikiewicz P, Międzybrodzki R, Nowak S, et al. Immune response to therapeutic staphylococcal bacteriophages in mammals: Kinetics of induction, immunogenic structural proteins, natural and induced antibodies. Frontiers in Immunology. 2021;12:639570. https://doi.org/10.3389/fimmu.2021.639570
81. Le HT, Venturini C, Lubian AF, Bowring B, Iredell J, et al. Differences in phage recognition and immunogenicity contribute to divergent human immune responses to Escherichia coli and Klebsiella pneumoniae phages. European Journal of Immunology. 2025;55(3):e202451543. https://doi.org/10.1002/eji.202451543
82. Berkson JD, Wate CE, Allen GB, Schubert AM, Dunbar KE, et al. Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin Resistant Enterococcus in a murine model. Nature Communications. 2024;15:2993. https://doi.org/10.1038/s41467-024-47192-w
83. Champagne-Jorgensen K, Luong T, Darby T, Roach DR. Immunogenicity of bacteriophages. Trends in Microbiology. 2023;31(10):1058–1071. https://doi.org/10.1016/j.tim.2023.04.008
84. Dąbrowska K, Miernikiewicz P, Piotrowicz A, Hodyra K, Owczarek B, et al. Immunogenicity studies of proteins forming the T4 phage head surface. Journal of Virology. 2014;88(21):12551–12557. https://doi.org/10.1128/jvi.02043-14
85. Olawade DB, Fapohunda O, Egbon E, Ebiesuwa OA, Usman SO, et al. Phage therapy: A targeted approach to overcoming antibiotic resistance. Microbial Pathogenesis. 2024;197:107088. https://doi.org/10.1016/j.micpath.2024.107088
86. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, et al. Quality and safety requirements for sustainable phage therapy products. Pharmaceutical Research. 2015;32:2173–2179. https://doi.org/10.1007/s11095-014-1617-7
87. Wang B, Du L, Dong B, Kou E, Wang L, et al. Current knowledge and perspectives of phage therapy for combating refractory wound infections. International Journal of Molecular Sciences. 2024;25(10):5465. https://doi.org/10.3390/ijms25105465
88. Pal N, Sharma P, Kumawat M, Singh S, Verma V, et al. Phage therapy: An alternative treatment modality for MDR bacterial infections. Infectious Diseases. 2024;56(10):785–817. https://doi.org/10.1080/23744235.2024.2379492
89. Nikulin N, Nikulina A, Zimin A, Aminov R. Phages for treatment of Escherichia coli infections. Progress in Molecular Biology and Translational Science. 2023;200:171–206. https://doi.org/10.1016/bs.pmbts.2023.03.011
